METHODS AND DEVICES FOR ENDOVASCULAR ABLATION OF A SPLANCHNIC

Patent specification available for detailed information.

The Problem

Heart failure (HF) is a medical condition that occurs when the heart is unable to pump sufficiently to sustain the organs of the body. Heart failure is a serious condition and affects millions of patients in the United States and around the world. One common measure of heart health is left ventricular ejection fraction (LVEF) or 25 ejection fraction. By definition, the volume of blood within a ventricle immediately before a contraction is known as the end-diastolic volume (EDV). Likewise, the volume of blood left in a ventricle at the end of contraction is end-systolic volume (ESV). The difference between EDV and ESV is stroke volume (SV). SV describes the volume of blood ejected from the right and left ventricles with each heartbeat. Ejection fraction (EF) is the fraction of the EDV that is ejected with each beat; that is, it is SV divided by EDV. Cardiac output (CO) is defined as the 30 volume of blood pumped per minute by each ventricle of the heart. CO is equal to SV times the heart rate (HR). – 1 – wo 2021/146724 PCT/US2021/014001 Cardiomyopathy, in which the heart muscle becomes weakened, stretched, or 26 Feb 2026 exhibits other structural problems, can be further categorized

In existing solutions, practitioners face limitations in achieving desired outcomes efficiently. This invention directly addresses these gaps by introducing novel technical approaches and mechanisms.

What This Invention Does

DETAILED DESCRIPTION 30 – 2 WO 2021/146724 PCT/US2021/014001 26 Feb 2026 greater splanchnic nerve (“GSN”), lesser splanchnic nerve, or least splanchnic nerve or one of 5 (i. , most caudal) three intercostal veins (which may be T9, T10, or T11). Figure 1 shows a patient’s thoracic spine, including T12 (62), T11 (63), T10 (64), and T9 (65) vertebrae, intervertebral discs, a sympathetic trunk 54, an azygos vein 50, a right 10 53, and a fully-formed GSN 52.

The integration of these technical elements creates a system capable of delivering improved performance over existing alternatives. The inventors have identified and implemented solutions to key challenges that have limited previous approaches in this field.

Key Features

Innovative Technical Integration. The system seamlessly combines multiple functional components to work as a coordinated whole, enabling capabilities that would be difficult or impossible with standalone elements.

Dynamic Parameter Management. The invention includes mechanisms for adapting operational parameters based on conditions and requirements, allowing for optimized performance across diverse scenarios.

Enhanced Efficiency and Capability. Through its novel architecture and control mechanisms, the system achieves superior performance metrics compared to conventional approaches in the field.

Who Is Behind It?

Axon Vascular, Inc. has brought this innovation to the patent system with expertise from a skilled team of inventors: MCGRATH, Thomas Ryan; AHONEN, Anne Marie; BAPNA, Anisha; ENGELMAN, Zoar Jacob; LEVIN, Howard; VANDILLEN, Nicholas C.; MILLER, Casey Andrew; IRANITALAB, Pajhand; JAVIER Jr., Manuel Arzadon. This represents their commitment to advancing technology in this important field.

Why It Matters

This patent application demonstrates significant innovation in an important technical area. The solutions described in the specification have the potential to improve how practitioners approach problems and deliver value in real-world applications.

The international patent classifications include A61B 18/14 (2006.01) A61B 18/12 (2006.01) A61B 18/08 (2006.01) A61M 25/00 (2006.01). These codes situate the invention within the broader landscape of technological innovation and represent important areas of advancement.

---

AU 2026201451 was published in the Australian Official Journal of Patents on 19 March 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.

Related Concepts

Heart failure affects millions worldwide, driving research into novel therapies that target its autonomic drivers. The splanchnic nerves modulate venous capacitance and blood volume distribution; disrupting this pathway via endovascular catheter ablation can reduce cardiac preload. The technique builds on the established safety profile of intravascular catheter-based procedures already used in cardiac electrophysiology.